$NRXP FDA approved preservative-free ketamine ANDA, premarket gap up 14.7% to $3.04 from $2.66 prior close on 4.83M shares. Tapeboard flagged it… https://tapeboard.com/go/bsky/scanner?utm_source=bluesky&utm_medium=post&utm_campaign=bsky-native&utm_content=nrxp-pm-up-scanner&utm_term=scanner&s=NRXP
October 30, 2026 at 12:07 PM
$NRXP FDA approved preservative-free ketamine ANDA, premarket gap up 14.7% to $3.04 from $2.66 prior close on 4.83M shares. Tapeboard flagged it… https://tapeboard.com/go/bsky/scanner?utm_source=bluesky&utm_medium=post&utm_campaign=bsky-native&utm_content=nrxp-pm-up-scanner&utm_term=scanner&s=NRXP
$NRXP FDA approved preservative-free ketamine ANDA, premarket gap up 14.7% to $3.04 from $2.66 prior close on 4.83M shares. Tapeboard flagged it… https://tapeboard.com/go/bsky/scanner?utm_source=bluesky&utm_medium=post&utm_campaign=bsky-native&utm_content=nrxp-pm-up-scanner&utm_term=scanner&s=NRXP
October 30, 2026 at 12:07 PM
$NRXP FDA approved preservative-free ketamine ANDA, premarket gap up 14.7% to $3.04 from $2.66 prior close on 4.83M shares. Tapeboard flagged it… https://tapeboard.com/go/bsky/scanner?utm_source=bluesky&utm_medium=post&utm_campaign=bsky-native&utm_content=nrxp-pm-up-scanner&utm_term=scanner&s=NRXP
BUY $NRXP (NRXP.O) [FDA] Product Approval @ 11:00:02Z
October 30, 2026 at 11:00 AM
BUY $NRXP (NRXP.O) [FDA] Product Approval @ 11:00:02Z
$NRXP Session: premarket. gap up 10.8% to $2.95 from $2.66 prior close on 1,448,871 shares. running hot this session - these verticals can fade fast… https://tapeboard.com/go/bsky/scanner?utm_source=bluesky&utm_medium=post&utm_campaign=bsky-native&utm_content=nrxp-pm-up-tape&utm_term=scanner&s=NRXP
October 30, 2026 at 10:06 AM
$NRXP Session: premarket. gap up 10.8% to $2.95 from $2.66 prior close on 1,448,871 shares. running hot this session - these verticals can fade fast… https://tapeboard.com/go/bsky/scanner?utm_source=bluesky&utm_medium=post&utm_campaign=bsky-native&utm_content=nrxp-pm-up-tape&utm_term=scanner&s=NRXP
$NRXP Session premarket gap up 14.5% to $3.08 from $2.66 prior close on 605,297 shares. NRx Pharmaceuticals to host conference call on October 30, 2… https://tapeboard.com/go/bsky/scanner?utm_source=bluesky&utm_medium=post&utm_campaign=bsky-native&utm_content=nrxp-pm-up-tape&utm_term=scanner&s=NRXP
October 30, 2026 at 8:05 AM
$NRXP Session premarket gap up 14.5% to $3.08 from $2.66 prior close on 605,297 shares. NRx Pharmaceuticals to host conference call on October 30, 2… https://tapeboard.com/go/bsky/scanner?utm_source=bluesky&utm_medium=post&utm_campaign=bsky-native&utm_content=nrxp-pm-up-tape&utm_term=scanner&s=NRXP
$NRXP Session: premarket. gap up 10.8% to $2.95 from $2.66 prior close on 1,448,871 shares. running hot this session - these verticals can fade fast… https://tapeboard.com/go/bsky/scanner?utm_source=bluesky&utm_medium=post&utm_campaign=bsky-native&utm_content=nrxp-pm-up-tape&utm_term=scanner&s=NRXP
October 30, 2026 at 10:06 AM
$NRXP Session: premarket. gap up 10.8% to $2.95 from $2.66 prior close on 1,448,871 shares. running hot this session - these verticals can fade fast… https://tapeboard.com/go/bsky/scanner?utm_source=bluesky&utm_medium=post&utm_campaign=bsky-native&utm_content=nrxp-pm-up-tape&utm_term=scanner&s=NRXP
$NRXP Session premarket gap up 14.5% to $3.08 from $2.66 prior close on 605,297 shares. NRx Pharmaceuticals to host conference call on October 30, 2… https://tapeboard.com/go/bsky/scanner?utm_source=bluesky&utm_medium=post&utm_campaign=bsky-native&utm_content=nrxp-pm-up-tape&utm_term=scanner&s=NRXP
October 30, 2026 at 8:05 AM
$NRXP Session premarket gap up 14.5% to $3.08 from $2.66 prior close on 605,297 shares. NRx Pharmaceuticals to host conference call on October 30, 2… https://tapeboard.com/go/bsky/scanner?utm_source=bluesky&utm_medium=post&utm_campaign=bsky-native&utm_content=nrxp-pm-up-tape&utm_term=scanner&s=NRXP
$NRXP 🏥
NRx Pharmaceuticals, Inc. received FDA approval for its preservative-free ketamine presentation ahead of the November 10 FDA goal date.
Prioritized by relevance
More market highlights:
https://rayvio.app/dashboard/?utm_source=lifatpt
NRx Pharmaceuticals, Inc. received FDA approval for its preservative-free ketamine presentation ahead of the November 10 FDA goal date.
Prioritized by relevance
More market highlights:
https://rayvio.app/dashboard/?utm_source=lifatpt
October 30, 2026 at 11:02 AM
$NRXP 🏥
NRx Pharmaceuticals, Inc. received FDA approval for its preservative-free ketamine presentation ahead of the November 10 FDA goal date.
Prioritized by relevance
More market highlights:
https://rayvio.app/dashboard/?utm_source=lifatpt
NRx Pharmaceuticals, Inc. received FDA approval for its preservative-free ketamine presentation ahead of the November 10 FDA goal date.
Prioritized by relevance
More market highlights:
https://rayvio.app/dashboard/?utm_source=lifatpt
#NRXP NRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date
https://www.stocktitan.net/news/NRXP/n-rx-pharmaceuticals-nasdaq-nrxp-receives-fda-approval-of-tnzh5u7rfta7.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/NRXP/n-rx-pharmaceuticals-nasdaq-nrxp-receives-fda-approval-of-tnzh5u7rfta7.html?utm_source=stocktitan-bluesky&utm_medium=social
NRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date
NRx Pharmaceuticals (Nasdaq: NRXP) received FDA approval of its generic drug application for preservative-free ketamine ahead of the agency’s goal date.The approval preceded the November 10 target. The formulation contains no benzethonium chloride, a preservative used in existing ketamine injections. Manufactured commercial supply is on hand; NRx said it can now label the product and supply American hospitals and clinics.The product is manufactured in the United States with Nephron Pharmaceuticals in West Columbia, South Carolina. NRx aims to address the shortage of traditional glass-bottled ketamine through high-volume “blow-fill-seal” manufacturing technology. The company said ketamine injection has been in short supply since 2018 and currently appears on the FDA drug shortage list.
www.stocktitan.net
October 30, 2026 at 11:00 AM
#NRXP NRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date
https://www.stocktitan.net/news/NRXP/n-rx-pharmaceuticals-nasdaq-nrxp-receives-fda-approval-of-tnzh5u7rfta7.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/NRXP/n-rx-pharmaceuticals-nasdaq-nrxp-receives-fda-approval-of-tnzh5u7rfta7.html?utm_source=stocktitan-bluesky&utm_medium=social
#$NRXP weekly close $2.27 (-8.8% w/w), below SMA50 $3.06 / below SMA200 $2.97, RSI 29.9. Support $2.11, resistance $2.98. Broad market sell-off Friday.
Oct 30: FDA approved its preservative-free ketamine ANDA.
New hub updated: www.merlintrader.com/nrx-pharmace...
Oct 30: FDA approved its preservative-free ketamine ANDA.
New hub updated: www.merlintrader.com/nrx-pharmace...
October 31, 2026 at 1:27 PM
#$NRXP weekly close $2.27 (-8.8% w/w), below SMA50 $3.06 / below SMA200 $2.97, RSI 29.9. Support $2.11, resistance $2.98. Broad market sell-off Friday.
Oct 30: FDA approved its preservative-free ketamine ANDA.
New hub updated: www.merlintrader.com/nrx-pharmace...
Oct 30: FDA approved its preservative-free ketamine ANDA.
New hub updated: www.merlintrader.com/nrx-pharmace...
#$NRXP weekly close $2.27 (-8.8% w/w), below SMA50 $3.06 / below SMA200 $2.97, RSI 29.9. Support $2.11, resistance $2.98. Broad market sell-off Friday.
Oct 30: FDA approved its preservative-free ketamine ANDA.
New hub updated: www.merlintrader.com/nrx-pharmace...
Oct 30: FDA approved its preservative-free ketamine ANDA.
New hub updated: www.merlintrader.com/nrx-pharmace...
October 31, 2026 at 1:27 PM
#$NRXP weekly close $2.27 (-8.8% w/w), below SMA50 $3.06 / below SMA200 $2.97, RSI 29.9. Support $2.11, resistance $2.98. Broad market sell-off Friday.
Oct 30: FDA approved its preservative-free ketamine ANDA.
New hub updated: www.merlintrader.com/nrx-pharmace...
Oct 30: FDA approved its preservative-free ketamine ANDA.
New hub updated: www.merlintrader.com/nrx-pharmace...
Biotech Radar Oct 30: #$ABOS stops sabirnetug after ALTITUDE-AD miss; #$AGIO mitapivat FDA date moved to Feb 1, 2027; #$NRXP announces ketamine ANDA approval; #$REGN Q3 revenue +36%.
www.merlintrader.com/biotech-rada...
www.merlintrader.com/biotech-rada...
October 30, 2026 at 10:49 PM
Biotech Radar Oct 30: #$ABOS stops sabirnetug after ALTITUDE-AD miss; #$AGIO mitapivat FDA date moved to Feb 1, 2027; #$NRXP announces ketamine ANDA approval; #$REGN Q3 revenue +36%.
www.merlintrader.com/biotech-rada...
www.merlintrader.com/biotech-rada...
$NRXP: conference call today at 8:30 am ET on a regulatory milestone for the Preservative-Free Ketamine program; press release expected before the open. Not investment advice.
https://www.merlintrader.com/nrx-pharmaceuticals-stock-hub/
https://www.merlintrader.com/nrx-pharmaceuticals-stock-hub/
$NRXP: conference call today at 8:30 am ET on a regulatory milestone for the Preservative-Free Ketamine program; press release expected before the open. Not investment advice.
www.merlintrader.com
October 30, 2026 at 8:24 AM
$NRXP: conference call today at 8:30 am ET on a regulatory milestone for the Preservative-Free Ketamine program; press release expected before the open. Not investment advice.
https://www.merlintrader.com/nrx-pharmaceuticals-stock-hub/
https://www.merlintrader.com/nrx-pharmaceuticals-stock-hub/
$NRXP: conference call today at 8:30 am ET on a regulatory milestone for the Preservative-Free Ketamine program; press release expected before the open. Not investment advice.
https://www.merlintrader.com/nrx-pharmaceuticals-stock-hub/
https://www.merlintrader.com/nrx-pharmaceuticals-stock-hub/
$NRXP: conference call today at 8:30 am ET on a regulatory milestone for the Preservative-Free Ketamine program; press release expected before the open. Not investment advice.
www.merlintrader.com
October 30, 2026 at 8:24 AM
$NRXP: conference call today at 8:30 am ET on a regulatory milestone for the Preservative-Free Ketamine program; press release expected before the open. Not investment advice.
https://www.merlintrader.com/nrx-pharmaceuticals-stock-hub/
https://www.merlintrader.com/nrx-pharmaceuticals-stock-hub/
Biotech Radar Oct 30: #$ABOS stops sabirnetug after ALTITUDE-AD miss; #$AGIO mitapivat FDA date moved to Feb 1, 2027; #$NRXP announces ketamine ANDA approval; #$REGN Q3 revenue +36%.
www.merlintrader.com/biotech-rada...
www.merlintrader.com/biotech-rada...
October 30, 2026 at 10:49 PM
Biotech Radar Oct 30: #$ABOS stops sabirnetug after ALTITUDE-AD miss; #$AGIO mitapivat FDA date moved to Feb 1, 2027; #$NRXP announces ketamine ANDA approval; #$REGN Q3 revenue +36%.
www.merlintrader.com/biotech-rada...
www.merlintrader.com/biotech-rada...
$NRXP Oct 29: call set for Oct 30, 8:30 a.m. ET, on a Preservative-Free Ketamine regulatory milestone (details not yet public). ANDA goal date: Nov 10. Rebuilt hub with the 42-page PDF report. Not investment advice.
https://www.merlintrader.com/nrx-pharmaceuticals-stock-hub/?v=snello
https://www.merlintrader.com/nrx-pharmaceuticals-stock-hub/?v=snello
NRXP Stock: NRx Pharmaceuticals News, Ketamine & Financing
NRx Pharmaceuticals stock news: November 10 generic ketamine goal date, June cash of $26.7M, clinic revenue, DARPA funding and dilution risks.
www.merlintrader.com
October 30, 2026 at 12:55 AM
$NRXP Oct 29: call set for Oct 30, 8:30 a.m. ET, on a Preservative-Free Ketamine regulatory milestone (details not yet public). ANDA goal date: Nov 10. Rebuilt hub with the 42-page PDF report. Not investment advice.
https://www.merlintrader.com/nrx-pharmaceuticals-stock-hub/?v=snello
https://www.merlintrader.com/nrx-pharmaceuticals-stock-hub/?v=snello
$NRXP Oct 29: call set for Oct 30, 8:30 a.m. ET, on a Preservative-Free Ketamine regulatory milestone (details not yet public). ANDA goal date: Nov 10. Rebuilt hub with the 42-page PDF report. Not investment advice.
https://www.merlintrader.com/nrx-pharmaceuticals-stock-hub/?v=snello
https://www.merlintrader.com/nrx-pharmaceuticals-stock-hub/?v=snello
NRXP Stock: NRx Pharmaceuticals News, Ketamine & Financing
NRx Pharmaceuticals stock news: November 10 generic ketamine goal date, June cash of $26.7M, clinic revenue, DARPA funding and dilution risks.
www.merlintrader.com
October 30, 2026 at 12:55 AM
$NRXP Oct 29: call set for Oct 30, 8:30 a.m. ET, on a Preservative-Free Ketamine regulatory milestone (details not yet public). ANDA goal date: Nov 10. Rebuilt hub with the 42-page PDF report. Not investment advice.
https://www.merlintrader.com/nrx-pharmaceuticals-stock-hub/?v=snello
https://www.merlintrader.com/nrx-pharmaceuticals-stock-hub/?v=snello
🔭 Arena watchlist · Fri Oct 30
Early movers our paper traders are watching: WKHS +18%, NXTT +11%, INLX +10%, NCPL +12%, NRXP +13%. Watch them call entries and exits live, with the Scout reading the tape out loud.
https://suggestionbox.live/arena/day/
Paper trades, not advice.
Early movers our paper traders are watching: WKHS +18%, NXTT +11%, INLX +10%, NCPL +12%, NRXP +13%. Watch them call entries and exits live, with the Scout reading the tape out loud.
https://suggestionbox.live/arena/day/
Paper trades, not advice.
Day-Trading Experiments · SuggestionBox.Live
Paper traders on live small caps, narrated move by move. Losers included. Not advice.
suggestionbox.live
October 30, 2026 at 11:15 AM
🔭 Arena watchlist · Fri Oct 30
Early movers our paper traders are watching: WKHS +18%, NXTT +11%, INLX +10%, NCPL +12%, NRXP +13%. Watch them call entries and exits live, with the Scout reading the tape out loud.
https://suggestionbox.live/arena/day/
Paper trades, not advice.
Early movers our paper traders are watching: WKHS +18%, NXTT +11%, INLX +10%, NCPL +12%, NRXP +13%. Watch them call entries and exits live, with the Scout reading the tape out loud.
https://suggestionbox.live/arena/day/
Paper trades, not advice.
🔭 Arena watchlist · Fri Oct 30
Early movers our paper traders are watching: WKHS +18%, NXTT +11%, INLX +10%, NCPL +12%, NRXP +13%. Watch them call entries and exits live, with the Scout reading the tape out loud.
https://suggestionbox.live/arena/day/
Paper trades, not advice.
Early movers our paper traders are watching: WKHS +18%, NXTT +11%, INLX +10%, NCPL +12%, NRXP +13%. Watch them call entries and exits live, with the Scout reading the tape out loud.
https://suggestionbox.live/arena/day/
Paper trades, not advice.
Day-Trading Experiments · SuggestionBox.Live
Paper traders on live small caps, narrated move by move. Losers included. Not advice.
suggestionbox.live
October 30, 2026 at 11:15 AM
🔭 Arena watchlist · Fri Oct 30
Early movers our paper traders are watching: WKHS +18%, NXTT +11%, INLX +10%, NCPL +12%, NRXP +13%. Watch them call entries and exits live, with the Scout reading the tape out loud.
https://suggestionbox.live/arena/day/
Paper trades, not advice.
Early movers our paper traders are watching: WKHS +18%, NXTT +11%, INLX +10%, NCPL +12%, NRXP +13%. Watch them call entries and exits live, with the Scout reading the tape out loud.
https://suggestionbox.live/arena/day/
Paper trades, not advice.
$NRXP Premium report, now with a downloadable 44-page PDF. FDA GDUFA goal date Nov 10 for preservative-free IV ketamine; cash $26.7M at June 30 with a going-concern doubt.
https://www.merlintrader.com/nrx-pharmaceuticals-stock-hub/
https://www.merlintrader.com/nrx-pharmaceuticals-stock-hub/
NRx Pharmaceuticals ($NRXP): The November 10 FDA Date
NRXP before the November 10, 2026 GDUFA date on preservative-free ketamine: deficiency cut to minor, $26.7M cash with going-concern doubt, 22.6% short interest.
www.merlintrader.com
October 26, 2026 at 2:04 PM
$NRXP Premium report, now with a downloadable 44-page PDF. FDA GDUFA goal date Nov 10 for preservative-free IV ketamine; cash $26.7M at June 30 with a going-concern doubt.
https://www.merlintrader.com/nrx-pharmaceuticals-stock-hub/
https://www.merlintrader.com/nrx-pharmaceuticals-stock-hub/
#$NRXP rose 3.8% Friday to $2.49, still below the 50-day EMA ($3.03) and the 200-day ($2.97). The 20-day range is $2.24-$3.06; tested resistance at $3.63-$3.74. RSI 32.
Interactive chart at JC Just Charts: justcharts.merlintrader.com#NRXP
Not investment advice.
Interactive chart at JC Just Charts: justcharts.merlintrader.com#NRXP
Not investment advice.
JustCharts: Stock Charts & Technical Analysis | Merlintrader
Explore US stock charts with EMA 50 and 200, support, resistance, trendlines and conditional technical scenarios. Daily data from the Merlintrader hub universe.
justcharts.merlintrader.com
October 25, 2026 at 12:53 PM
#$NRXP rose 3.8% Friday to $2.49, still below the 50-day EMA ($3.03) and the 200-day ($2.97). The 20-day range is $2.24-$3.06; tested resistance at $3.63-$3.74. RSI 32.
Interactive chart at JC Just Charts: justcharts.merlintrader.com#NRXP
Not investment advice.
Interactive chart at JC Just Charts: justcharts.merlintrader.com#NRXP
Not investment advice.
NRx completed process validation lots and two-year stability data for preservative-free ketamine ahead of the Nov 10 GDUFA date. $NRXP
https://www.merlintrader.com/nrx-pharmaceuticals-stock-hub/
https://www.merlintrader.com/nrx-pharmaceuticals-stock-hub/
NRx Pharmaceuticals ($NRXP): The November 10 FDA Date
NRXP before the November 10, 2026 GDUFA date on preservative-free ketamine: deficiency cut to minor, $26.7M cash with going-concern doubt, 22.6% short interest.
www.merlintrader.com
October 19, 2026 at 4:14 PM
NRx completed process validation lots and two-year stability data for preservative-free ketamine ahead of the Nov 10 GDUFA date. $NRXP
https://www.merlintrader.com/nrx-pharmaceuticals-stock-hub/
https://www.merlintrader.com/nrx-pharmaceuticals-stock-hub/
#NRXP NRx Pharmaceuticals (Nasdaq:NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Fr…
https://www.stocktitan.net/news/NRXP/n-rx-pharmaceuticals-nasdaq-nrxp-announces-completion-of-qz6p9u83h68n.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/NRXP/n-rx-pharmaceuticals-nasdaq-nrxp-announces-completion-of-qz6p9u83h68n.html?utm_source=stocktitan-bluesky&utm_medium=social
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free Ketamine
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
October 19, 2026 at 12:30 PM
#NRXP NRx Pharmaceuticals (Nasdaq:NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Fr…
https://www.stocktitan.net/news/NRXP/n-rx-pharmaceuticals-nasdaq-nrxp-announces-completion-of-qz6p9u83h68n.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/NRXP/n-rx-pharmaceuticals-nasdaq-nrxp-announces-completion-of-qz6p9u83h68n.html?utm_source=stocktitan-bluesky&utm_medium=social
NRx Pharmaceuticals (#$NRXP) completed three commercial-scale validation lots of its preservative-free ketamine. ANDA’s FDA goal date is Nov. 10; approval is not assured.
prismmarketview.com/nrx-complete...
prismmarketview.com/nrx-complete...
NRx Completes Ketamine Manufacturing Validation Ahead of November FDA Review Target
Key Points NRx Pharmaceuticals completed three commercial-scale validation lots of its preservative-free ketamine. Two-year room-temperature testing sho
prismmarketview.com
October 19, 2026 at 2:47 PM
NRx Pharmaceuticals (#$NRXP) completed three commercial-scale validation lots of its preservative-free ketamine. ANDA’s FDA goal date is Nov. 10; approval is not assured.
prismmarketview.com/nrx-complete...
prismmarketview.com/nrx-complete...
